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Background: While treatment with levodopa remains the cornerstone of
Parkinson’s disease (PD) management, chronic oral therapy is often associated
with the development of motor complications, that correlate to ﬂuctuating
levodopa plasma concentrations, limiting its clinical utility. Continuous infusion
is considered to be the optimal delivery route for treating PD patients with
motor ﬂuctuations, but current infusion systems require invasive surgery.
Subcutaneous infusion of (SC) levodopa has the potential to provide a
better tolerated and more convenient route of continuous levodopa delivery.
ND0612 is in development as a combination product providing continuous
levodopa/carbidopa via a minimally invasive, subcutaneous delivery system
for PD patients experiencing motor response ﬂuctuations. We present
pharmacokinetic results from a series of studies that analyzed plasma
concentrations after SC levodopa delivery with ND0612 to inform the clinical
development program.
Methods: We performed a series of six Phase I and II studies to characterize the
pharmacokinetics of levodopa and carbidopa derived from ND0612 infusion
with/without adjunct oral therapy of the same ingredients. These studies
were conducted in healthy volunteers and in PD patients experiencing motor
response ﬂuctuations while on their current levodopa therapy regimen.
Results: Taken together, the results demonstrate dose-proportionality
dependent on rate of subcutaneous levodopa infusion leading to stable
and sustained plasma concentrations of levodopa. Subcutaneous infusion
of ND0612 administered with oral levodopa/carbidopa maintained nearconstant, therapeutic levodopa plasma concentrations, thereby avoiding the
troughs in levodopa plasma concentrations that are associated with OFF time
in PD. The data generated in this series of studies also conﬁrmed that a
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levodopa/carbidopa dose ratio of 8:1 would be the most reasonable choice
for ND0612 development.
Conclusions:
This series of clinical pharmacokinetic studies have
demonstrated that ND0612, administered continuously with a levodopa
concentration of 60 mg/ml combined with carbidopa 7.5 mg/ml, and
complemented with oral levodopa/carbidopa, is suitable for 24 h continuous
administration in patients with PD. The stable plasma concentrations of
levodopa achieved predict utility of ND0612 as a parenteral formulation for
achieving clinically useful delivery of levodopa for PD patients.
KEYWORDS

carbidopa, clinical
pharmacokinetics

Introduction

levodopa,

ND0612,

Parkinson’s

disease,

much of the blame for motor fluctuations falls on inconsistent
gastrointestinal mechanisms leading to insufficient absorption of
the drug, substantial intraindividual variability (14), and delayed
onset of its antiparkinsonian effects (15, 16). Declining efficiency
of the stomach to deliver oral levodopa to its sole absorption site
in the proximal small intestine has been recognized as one of the
consequences of chronic PD (16). Gastrointestinal dysfunction
is frequent in PD, eventually affecting almost all patients during
their disease course (16–18). For example, prolonged gastric
emptying time can occur throughout the course of PD (18),
and orally-administered levodopa can itself increase gastric acid
secretion, impair gastric relaxation, and delay gastric emptying
(19, 20).
Continuous levodopa delivery to the brain has not been
possible to achieve with orally-dosed levodopa, even with
pharmacological advances designed to achieve greater extension
of levodopa release as compared to the immediate-release
formulation (19). Drugs designed to block the peripheral
catabolism of levodopa [catechol-O-methyltransferase (COMT)
inhibitors] or retard the oxidative deamination of dopamine
in the brain (monoamine oxidase-B inhibitors) achieve only a
limited extension in duration of antiparkinsonian effect (21–
23). When a patient has lost the long-duration response, the
short plasma half-life of levodopa (∼90–150 min) will require
that immediate-release products be dosed repeatedly at intervals
as close as 2–3 hourly intervals (22). Clinical experience shows
that even these strategies, combined with MAO-B and COMT
inhibitors, often fail to accomplish continuity of levodopa
effect (24, 25). Thus, there has been a keen interest to
improve levodopa therapeutics by optimizing its delivery to
the brain by means of an alternative to its oral (and therefore
gastrointestinal) delivery.
Pharmacodynamic
studies
exploring
continuous
intravenous levodopa infusion into a patient with PD first
revealed the potential offered by parenteral levodopa delivery
(26). Another route of administration has been developed

Although more than two dozen drugs have undergone
human testing as alternatives for achieving striatal dopaminergic
stimulation, levodopa remains the most effective drug for
controlling the motor symptoms of Parkinson’s disease
(PD) (1, 2). Most patients receiving levodopa chronically
experience continuing benefits, although the consistency of
antiparkinsonian effect from each oral dose tends to decline
over time. A key driver in the search for improved therapies has
been the problem of motor complications (response fluctuations
and dyskinesia) that can develop with long-term levodopa use.
Recent cohort studies estimate the 5-year cumulative incidence
of response fluctuations and dyskinesias ranges between 29
and 54% in the overall levodopa-treated PD population (3–5),
increasing to near-universal occurrence after 10 years or
more of continuing levodopa use (5). These problems have
significant impact on employment, independent functioning,
safety, and quality of life (3, 6–10), particularly in patients
with a younger age of onset (4). Response fluctuations evolve
as patients experience the waning of the “long duration”
response to levodopa dosing over time [the sustained motor
improvement that builds up slowly and can persist for days
after each dose (5)] and the “short duration” response (in
which the therapeutic response closely parallels the plasma
pharmacokinetics of levodopa) starts to predominate (11).
The major pharmacodynamic challenge for optimizing PD
therapeutics has been to reduce the variability of circulating
levodopa concentrations to overcome the problems of the short
duration response in order to lessen fluctuations in both motor
and non-motor signs and symptoms.
Whereas, OFF states can have other causes to explain
why PD patients are unresponsive to striatal dopaminergic
stimulation (such as the phenomenon of gait freezing), the most
common explanation for motor fluctuations is simply that of
inconsistent levodopa delivery to the brain (11–13). Indeed,
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Pharmacokinetic analyses

in a marketed product for infusion of a carbidopa-levodopa
suspension mixture continuously pumped into the proximal
small intestine (27, 28). Partial reduction of OFF time and
lessening of troublesome levodopa-induced dyskinesias has
been accomplished by per-gastric intestinal infusion by the
latter strategy. However, intra-intestinal delivery still delivers
levodopa through the intestinal wall and has practical and
tolerability issues that limit its use for the common problem
of irregular dopaminergic effect (29, 30). One potential
answer to the challenge of improving levodopa therapeutics is
ND0612 (NeuroDerm, Rehovot, Israel), a combination product
providing continuous levodopa/carbidopa via a minimally
invasive, subcutaneous (SC) delivery system in development
for people with PD experiencing motor fluctuations. As the
first levodopa liquid formulation created for SC delivery,
ND0612 has undergone a clinical development program with
a series of early Phase I and II studies for characterizing and
optimizing pharmacokinetics of its two key components,
levodopa and carbidopa.
We present pharmacokinetic results from a series of Phase
I and Phase II clinical studies that have analyzed plasma
concentrations and pharmacodynamics of SC levodopa delivery.
These studies informed the development of ND0612 as a PD
therapy for patients with motor response fluctuations and have
provided key information for its Phase III program. Clinical
experience from these studies have provided insights into the
pharmacokinetic behavior of levodopa and carbidopa when each
are administered subcutaneously.

During each treatment period, standardized meals with
a low content of protein were provided to minimize surges
of dietary-derived amino acids, which in some circumstances
may compete with levodopa uptake. Serial blood samples
for pharmacokinetic analysis of levodopa, carbidopa, and
the levodopa metabolite 3-O-Methyldopa (3-OMD) were
collected at relevant time points. Plasma levodopa, carbidopa,
and 3-OMD concentrations were analyzed using validated
liquid chromatography coupled to tandem mass spectrometry
(LC/MS/MS) methods.
For levodopa, the lower limit of quantitation (LLOQ) was
50 ng/ml, and the upper limit of quantitation (ULOQ) was
5,000 ng/ml. For carbidopa, the LLOQ was 10 ng/ml and the
ULOQ was 1,000 ng/ml. The pharmacokinetic population for
each study included all participants who had received at least
one dose of ND0612 and had a minimum of 3 quantifiable
post-dose plasma concentrations per analyte. Across the studies,
pharmacokinetic analysis of the concentration-time data was
performed using non-compartmental analysis to obtain the area
under the concentration-time curve (AUC) and the maximum
observed plasma concentrations (Cmax ).
In addition, Study 003 evaluated the time the plasma
concentration was above 1,000 ng/ml (T >1,000 ng/ml) (31) and
the Fluctuation Index calculated as (Cmax –Cmin )/Caverage (32).
Dose proportionality was assessed in Study 001 using a linear
regression analysis of log-transformed levodopa AUC15−24
and in Study 005 using a power model on log-transformed
AUC0−inf , AUC0−last , and Cmax , including terms for dose fitted
as a fixed (continuous) effect and participant as a random effect.

Methods
Study designs and participants

Safety analyses

We performed a series of six Phase I and II studies
to characterize the pharmacokinetics of levodopa and
carbidopa derived from ND0612 infusion with/without
adjunct oral therapy of the same active ingredients. These
studies were conducted in healthy volunteers and in PD
patients experiencing an established pattern of motor
fluctuations while on their current regimen of levodopa
and an inhibitor of aromatic L-amino acid decarboxylase,
also known as dopa-decarboxylase (DDC), either carbidopa
or benserazide. Table 1 provides an overview of the five
study methodologies and Supplementary Table 1 provides
further details per study. Each study was conducted in
accordance with the Declaration of Helsinki and International
Conference on Harmonization Good Clinical Practice
Guidelines. All participants provided written informed
consent. Institutional review boards at the participating
sites approved the study protocol, consent forms, and
associated amendments.

Safety was assessed in each of the studies through the
standard recording of adverse events. In addition, local
skin safety was specifically assessed across the studies. Skin
assessments typically included the assessment of nodules,
hematomas and pain.
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Results
Levodopa and carbidopa
pharmacokinetics
Studies 001 and 001b: Demonstration of stable
plasma levodopa concentrations following SC
delivery with ND0612 in healthy volunteers
Levodopa concentrations generally increased with
increasing infusion rates at a nearly dose proportional
manner. In Study 001, conducted in healthy volunteers, stable
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TABLE 1 Study methodologies.

Study

Objective

Study design

Participant type
(N)

Dosing & administration methods

ND0612-001

Demonstrate stable

Phase I, single dose

36 healthy male

• 24-h

plasma levodopa

(24-h), single-center,

volunteers (aged

(levodopa/carbidopa, 60/14 mg/ml) in one

concentrations

randomized,

18–40 years old)

infusion site and placebo on the opposite side of

following ND0612 SC

double-blind,

delivery in healthy

placebo-controlled

volunteers

dose escalation study

SC

infusion

of

ND0612

the abdomen.
• Doses

of

ND0612

were

administered

sequentially to cohorts of 6 volunteers.

(N=36)

• Infusion rates: 80, 120, 160, and 200 h (short
6 mm and regular 10 mm needles) 240 µL/h.

ND0612-001b

Determine the

Phase I, single dose

18 healthy male

steady-state plasma

(24-h), single-center,

volunteers (aged

concentration of

randomized,

18–40 years old)

levodopa and

double-blind,

carbidopa following

placebo-controlled

continuous SC

dose escalation study

delivery of ND0612 in

(N = 18)

• 24-h SC infusion of ND0612 in one infusion
site and placebo on the opposite side of the
abdomen.
• Doses of ND0612 were administered to 3
cohorts of 6 volunteers:
◦ Group A. ND0612 (50/11.7 mg/ml) at a rate of
240 µL/h over 24 h

healthy volunteers

◦ Group B. ND0612 (60/14 mg/ml) at a rate of 80
µL/h over 8 h and 240 µL/h over 16 h
◦ Group C. ND0612 (60/14 mg/ml) at a rate of
240 µL/h over 24 h administered with
entacapone 200 mg five times (every 2 h).

ND0612-002

• Patients were randomized (1:1) to ND0612

Establish

Single dose,

8 PD patients (Hoehn

pharmacokinetic

single-center,

and Yahr stage <5

(60/14 mg/ml at a rate of 0.08 ml/h over 8 h and

stability of levodopa

randomized,

during OFF) and

0.24 ml/h over 16 h) or placebo in the right side

levels in patients with

double-blind,

receiving optimized

Parkinson’s disease

placebo-controlled,

levodopa/L-AAAD

crossover study

inhibitor therapy (3–8

in the early evening and continued for 24 h. An

(N=8)

doses/day, not

oral tablet of fixed dose combination

exceeding 500

immediate-release

mg/day)

levodopa/carbidopa/entacapone (100/25/200)

of the abdomen.
• SC infusion of ND0612 or placebo was started

was administered at bedtime (∼3 h after the
start of the infusion) and in the morning on the
next day, 15 h after the start of the infusion.
Following a 1-week washout period, patients
received the other treatment in the left side.
ND0612-003 (35)

Evaluate levodopa

Randomized,

30 PD patients

pharmacokinetics

double-blind,

(Hoehn and Yahr

either ND0612 (60/14 mg/ml at a rate of 0.08

after repeated dose of

placebo- controlled,

stage <5 during OFF)

ml/h over 8 h and 0.24 ml/h over 16 h) or

ND0612 (14–21

parallel multidose

on an optimized oral

matching placebo in addition to their current

days), safety and

study (N = 30),

levodopa/L-AAAD

standard of care (SoC) treatment. Oral levodopa

tolerability and

followed by an

inhibitor regimen (≥3

dose reductions were permitted for improving

exploratory efficacy

open-label period (N

doses per day with

tolerability of the antiparkinsonian drug

analysis in PD

= 16)

≥3 h between doses)

regimen (such as troublesome dyskinesias), but

and experiencing ≥2

any changes in the levodopa dosing frequency

h/day of OFF time.

and interval were discouraged.

patients

• During Period 1, patients were randomized to

(Continued)
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TABLE 1 (Continued)

Study

Objective

Study design

Participant type
(N)

Dosing & administration methods

• The first 16 patients who completed Period-1
continued with open-label ND0612 treatment
during Period-2. These 16 patients were
re-randomized to receive 1 week of ND0612
monotherapy or ND0612 plus oral entacapone
while completely eliminating or reducing the
oral levodopa/carbidopa dose, based on
neurologist’s judgement.
ND0612-004

Evaluate levodopa

Open-label study in

16 PD patients on

plasma

which patients

optimized oral

concentrations when

received 2 to 3 of 6

levodopa/carbidopa

ND0612 is infused at

possible treatment

doses and

two different rates

regimens of ND0612,

experiencing

and at two different

for up to 3 days in

well-defined OFF

• While the concentration of levodopa (60 mg/ml)

carbidopa

separate, daily, 8-h

periods (≥80% of

remained constant, the carbidopa concentration

concentrations

consecutive infusion

days)

increased from 7.5 mg/ml on Day 1 to 14 mg/ml

periods (N = 16)

• Patients were assessed at baseline for standard of
care (oral levodopa/carbidopa)
• Patients were randomized to receive ND0612 at
either a low infusion (0.24 ml/h, n = 9) or a high
infusion (0.64 ml/h, n = 7) rate over 8 h.

on Day 3.
• On Day 4, patients received ND0612 (60/14
mg/ml) plus 200 mg entacapone.

ND0612-005

• ND0612 given at either a low dose

Identify the

Open-label study in

Healthy male and

concentration of

which patients

female volunteers

(administered through one infusion site,

infused carbidopa

received 1 of 2

(30–65 years old)

starting at 0.08 ml/h for 8 h and 0.24 ml/h for

that provides optimal

different regimens

16 h) or a high dose (administered through two

levodopa

containing 3 different

infusion sites, 0.08 ml/h for 6 h, 0.64 ml/h for

bioavailability in

LD/CD ratios (N =

18 h and changing back to 0.08 ml/h for an

healthy volunteers

20)

additional 6 h).
• While the concentration of levodopa (60
mg/ml) remained constant, the carbidopa
concentration tested was 7.5 mg/ml on Day 1, 6
mg/ml on Day 3, and 4 mg/ml on Day 5.

levodopa and carbidopa concentrations were already attained
by 15 h (timing of the first blood sample) of a 24-h continuous
infusion period, and the study participants maintained these
stable concentrations for the remainder of the 24-h infusion
period. Mean levodopa AUC15−24 values ranged from 1,413
h•ng/ml in the 80 µL/h group to 4,199 h•ng/ml in the 240
µL/h group. Linear regression analysis of log-transformed mean
AUC15−24 values demonstrated a slope value of 1.02 (95% CI:
0.92, 1.12) (Figure 1A). Mean AUC values of carbidopa from
15 to 24 h also increased with infusion rate. The average AUC
values ranged from 849 h•ng/ml in the 80 µL/h group (Group
1) to 2,201 h•ng/ml in the 240 µL/h group (Group 6). The
increase in carbidopa AUC15−24 , as a function of infusion rate,
was linear and proportional to rate of infusion demonstrating a
slope of 0.92 (95% CI: 0.78, 1.06). Similar results demonstrating
carbidopa dose proportionality were obtained for the maximum

Frontiers in Neurology

carbidopa concentration during the 15- to 24-h period and for
the mean carbidopa concentration at both 15 and 24 h of the
infusion period.
Similar results were seen in Study 001b where, consistent
with the results of the previous study, ND0612 administered
SC for 24 h achieved clinically relevant plasma concentrations
by at least 15 h (Figure 1B). An increase in the concentration
of ND0612 (from 50/11.7 to 60/14 mg/ml levodopa/carbidopa)
resulted in a corresponding increase in the mean AUC values
as would be expected (from 3,070 to 3,677 h•ng/ml). When
increasing the infusion rate 3-fold from 80 to 240 µL/h, mean
concentrations of levodopa increased over a 4–5-h period
and then stabilized. There was a further increase in levodopa
concentrations with the addition of entacapone (every 2 h for
the last 10 h of the 24-h infusion period) as would be expected
with inhibition of COMT activity.

05

frontiersin.org

LeWitt et al.

10.3389/fneur.2022.1036068

LD/CD/E dose for the remainder of the 24-h observation period
(Figure 2).
Both studies 002 and 003 used what can be considered a
“low” dose of ND0612 (total daily levodopa/carbidopa dose: 270
mg/63 mg). Key pharmacokinetic parameters for levodopa and
carbidopa (Cmax, AUC and fluctuation index) are summarized
for studies in patients with PD in Tables 2, 3.
Despite the low dose, Study 003 showed that continuous
SC administration of ND0612 + SoC oral levodopa/carbidopa
ameliorated the variability in levodopa plasma concentrations
as compared to placebo infusion + SoC. Patients treated with
ND0612 had their plasma levodopa concentrations consistently
maintained above a mean of 800 ng/ml, and completely avoided
the low trough concentrations observed in the placebo group
(Figure 3). There was also a significant increase in the duration
that levodopa concentrations above 1,000 ng/ml (mean increase
of 4.4 ± 2.2 h in a 10-h period, p < 0.0001) which was not
apparent in the placebo group (mean of 4.5 h at baseline and
at end of Period-1). The increase in mean levodopa exposure
achieved with ND0612 + SoC was accompanied by a decreased
variability in plasma levodopa concentrations, as evidenced by
a decreased Fluctuation Index vs. placebo + SoC (1.6 ± 0.5
vs. 3.1 ± 1.6, respectively, at end of Period-1). The addition of
entacapone to the continuous ND0612 SC infusion in Period
2 translated to an increase in mean levodopa AUC compared
with monotherapy.
FIGURE 1

Levodopa (A) area under the curve (B) concentrations over time
following SC infusion with ND0612 in healthy volunteers. (A)
AUC comparisons between cohorts were made on the 15- to
24-h time period after the start of the infusion (B) Blood samples
were collected at 11, 12, 13.5, 15 h for Group B only, and 16.5,
18, 19.5, 21, 22.5, and 24 h for all three groups.

Studies 004 and 005: Establishing the optimal
carbidopa concentration for ND0612
Study 004 explored the impact of two concentrations
of carbidopa in the formulation (7.5 and 14 mg/ml, giving
a LD/CD ratio of 8:1 and 4:1, respectively) on levodopa
concentrations. Both the low and high ND0612 regimens
maintained near-constant, therapeutic levodopa plasma
concentrations. Levodopa plasma concentrations were dose
proportional, with the high dose of 640 µL/h achieving around
3-fold higher plasma concentrations than the low dose 240
µL/h ND0612 regimen, which corresponds to the ∼3-fold
increase in daily levodopa dose infused. Figure 4 shows the
mean plasma levodopa concentrations following continuous SC
administration of low and high dose ND0612 with the different
carbidopa concentrations in the formulation as well as adding
entacapone to the high CD formulations.
The magnitude of the levodopa plasma concentration
differences between the two different ND0612 formulations
of carbidopa concentration is likely to be not clinically
relevant, with both concentrations achieving clinically relevant
levodopa concentrations as compared to the oral dosing
concentrations. Carbidopa exposure concentrations increased
proportionally with carbidopa dose. The addition of entacapone,
increased the steady state levodopa concentrations achieved with
both regimens.

Studies 002 and 003: Establishing the
pharmacokinetics of levodopa following SC
infusion with ND0612 in patients with PD
Stable levodopa and carbidopa concentration with ND0612
administration were also demonstrated in patients with PD.
In Study 002, where SC infusion of ND0612 started in the
early evening and one dose of an oral fixed combination
immediate-release levodopa/carbidopa/entacapone [LD/CD/E
(100/25/200)] was administered at bedtime (∼3 h after the start
of the infusion), stable levodopa concentrations were observed
from 9 h and stable carbidopa concentrations from 7 h until
the morning oral LD/CD/E dose (taken at 15 h). Increases in
overall levodopa and carbidopa concentrations (i.e., levodopa
and carbidopa from ND0612 + oral LD/CD/E) were observed
within 1 h of the morning oral LD/CD/E dose intake with
the peak levodopa concentrations occurring at 3 h post-oral
LD/CD/E intake; mean levodopa plasma concentrations were
sustained ≥25% higher than before administration of the oral
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FIGURE 2

Mean levodopa concentrations over time in patients with Parkinson’s disease. Blood sampling began at 7 h post-infusion start. Oral
levodopa/carbidopa/entacapone (100/25/200) was taken at 3- and 15-h post-infusion start.

TABLE 2 ND0612 levodopa pharmacokinetics in patients with Parkinson’s disease.

Study, N

Baseline
demographics

Concomitant
medications

N

Study 002

• Age, 66.9 ± 5.3

Amantadine (63%)

N=8

years

Regimen

ND0612 (60/14

Cmax
(ng/ml)
mean ± SD

Tmax (h)
median
(range)

AUC
(h•ng/ml)
mean ± SD

2,116 ± 390

3.0 (2.0–5.0)

AUC7−24 : 17,453 ±
3,206

Entacapone (38%)

mg/ml) at a rate of

• Male sex, 50.0%

Levodopa (100%)

0.08 ml/h over 8 h &

AUC15−∞ : 18,979

• White ethnicity,

Pramipexole (38%)

0.24 ml/h over 16 h

± 4,757

100%

plus Stalevo 100 given

• Duration of PD,

Rasagiline (63%)

at 3- and 15-h

8.1 ± 2.4 years

Ropinirole (38%)

post-infusion

• Duration of motor

Selegiline (38%)

fluctuations 2.9 ±
2.4 years
Study 003*

• Age, 63.8 ± 7.4

Amantadine (42%)

• Male sex, 63.2%

N = 19

Period 1: Standard of
care levodopa plus

years
Pramipexole (11%)

5.0 (0.0–10.0)

AUC0−10 : 19,592 ±
9,534

ND0612 (60/14
mg/ml) at a rate of

• White ethnicity,
Ropinirole (26%)

0.08 ml/h over 8 h &

• Duration of PD,

Rasagiline (42%)

0.24 ml/h

8.6 ± 4.5 years

Selegiline (21%)

over 16 h

100%

3,515 ± 1,452

(Continued)
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TABLE 2 (Continued)

Study, N

Baseline
demographics

Concomitant
medications

N

• Duration of motor

Trihexyphenidyl

N=8

Regimen

Period 2: ND0612

fluctuations 5.7 ±

(11%)

(60/14 mg/ml)

4.2 years

Biperiden (5%)

monotherapy at a rate

Cmax
(ng/ml)
mean ± SD

Tmax (h)
median
(range)

AUC
(h•ng/ml)
mean ± SD

1,185 ± 864

1.8 (0.0–10.0)

AUC0−10 : 7,297 ±
3,360

of 0.08 ml/h over 8 h
& 0.24 ml/h over 16 h
N=8

Period 2: ND0612

2,378 ± 1,553

1.0 (7.0–10.0)

60/14 mg/ml at a rate

AUC0−10 : 15,017 ±
7,669

of 0.08 ml/h over 8 h
& 0.24 ml/h over 16 h
plus entacapone
200 mg given every
6h
Study 004**

• Age, 63.0 ± 7.2

Amantadine (38%)

N=9

years
• Male sex, 75.0%

ND0612 (60/7.5

618 ± 496

7.0 (6.0–8.0)

mg/ml) at a low rate
Trihexyphenidyl

AUC 0−last : 2.487 ±
874

of 0.24 ml/h over 8 h

(6%)
• White ethnicity,

Pramipexole (25%)

N=9

100%
• Duration of PD,

Ropinirole (25%)

9.3 ± 3.9 years

Rasagiline (44%)

• Duration of motor

Selegiline (13%)

fluctuations 5.8 ±

ND0612 (60/14

487 ± 104

8.0 (7.0–8.0)

mg/ml) at a low rate

AUC 0−last : 2,434 ±
442

of 0.24 ml/h over 8 h

Biperiden (6%)

3.9 years
N=8

ND0612 (60/14

604 ± 106

8.0 (6.0–8.0)

mg/ml) at a low rate

AUC 0−last : 2,923 ±
518

of 0.24 ml/h over 8 h
plus entacapone
200 mg
N=7

ND0612 (60/7.5

1,355 ± 270

8.0 (8.0–8.0)

mg/ml) at a high rate

AUC 0−last : 6,466 ±
1,404

of 0.64 ml/h over 8 h
N=7

ND0612 (60/14

1,454 ± 270

8.0 (7.0–8.0)

mg/ml) at a high rate

AUC 0−last : 7,549 ±
1,621

of 0.64 ml/h over 8 h
N=7

ND0612 (60/14

1,844 ± 382

7.5 (7.0–8.0)

mg/ml) at a high rate

AUC 0−last : 8,853 ±
1,558

of 0.64 ml/h over 8 h
plus entacapone
200 mg
N = 16

Oral
levodopa/carbidopa

2,014 ± 861

1.5 (0.5–8.0)

AUC 0−last : 6,912 ±
3,077

(baseline)
*Data are for ND0612 are for end of study period. **Modified Fluctuation index (Model’s root mean square estimate).
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TABLE 3 ND0612 carbidopa pharmacokinetics in patients with Parkinson’s disease.

Study

N

Regimen

Study 002

N=8

ND0612 (60/14 mg/ml) monotherapy at a rate

Study 003*

N = 19

Period 1: Standard of care levodopa plus

Cmax
(ng/ml)
mean ± SD

Tmax (h)
median
(range)

AUC
(h•ng/ml)
mean ± SD

485 ± 102

4.5 (1.5–9.0)

AUC7−24 : 6,196

562 ± 112

6.0 (1.0–10.5)

AUC0−last : 5,082

of 0.08 ml/h over 8 h & 0.24 ml/h over 16 h

± 1,265

ND0612 (60/14 mg/ml) at a rate of 0.08 ml/h

± 985

over 8 h & 0.24 ml/h over 16 h
N=8

Period 2: ND0612 (60/14 mg/ml) monotherapy

538 ± 107

5.0 (0.0–9.0)

at a rate of 0.08 ml/h over 8 h & 0.24 ml/h over

AUC0−last : 4,744
± 942

16 h
N=8

Period 2: ND0612 60/14 mg/ml at a rate of 0.08

471± 86

6.0 (4.0–7.0)

ml/h over 8 h & 0.24 ml/h over 16 h plus

AUC0−last : 4,156
± 623

entacapone 200 mg given every 6 waking h
Study 004*

N=9

ND0612 (60/7.5 mg/ml) at a low rate of 0.24

N=9

ND0612 (60/14 mg/ml) at a low rate of 0.24

N=8

ND0612 (60/14 mg/ml) at a low rate of 0.24

N=7

ND0612 (60/7.5 mg/ml) at a high rate of 0.64

N=7

ND0612 (60/14 mg/ml) at a high rate of 0.64

N=7

ND0612 (60/14 mg/ml) at a high rate of 0.64

185 ± 37

8.0 (7.0–8.0)

AUC 0−last : 834 ±

351 ± 94

8.0 (7.0–8.0)

AUC 0−last : 1,590

346 ± 77

8.0 (7.0–8.0)

AUC 0−last : 1,633

477 ± 57

8.0 (7.0–8.0)

AUC 0−last : 2,120

879 ± 207

8.0 (7.0–8.0)

AUC 0−last : 4,173

835 ± 137

8.0 (6.0–8.0)

AUC 0−last : 4,096

ml/h over 8 h

114

ml/h over 8 h

± 309

ml/h over 8 h plus entacapone 200 mg

± 366

ml/h over 8 h

± 286

ml/h over 8 h

± 560

ml/h over 8 h plus entacapone 200 mg

± 587

*Data for ND0612 are for end of study period.

Safety and tolerability

The effect of carbidopa concentration was further studied
in the 005 study in healthy volunteers where study participants
received either low or high rates (doses) of SC ND0612 infusion
with three different carbidopa concentrations and ratios from
levodopa (7.5 mg/ml, 4:1; 6 mg/ml, 10:1; and 4 mg/ml, 15:1).
When administered at the low rate of infusion, mean [95%CI]
slope estimates for levodopa exposure on the linear mixed model
(log scale) were 0.004 (0.0002, 0.008) and 0.005 (0.001, 0.009)
for AUC0−last and AUC0−24 , respectively. These slope estimates
were statistically different from zero (p < 0.05), indicating that
levodopa AUC rose with increasing carbidopa dose. By contrast,
for the high rate of ND0612 infusion, levodopa exposure was
relatively unaffected by the carbidopa dose level, with no more
than a 5% difference in exposure over the dose range (Figure 5).
For both the high and low infusion rates, carbidopa
exposure increased in a dose-proportional manner with
respect to increasing carbidopa dose. The 7.5 mg/ml
dose of carbidopa consistently resulted in an AUC0−inf
above 2,000 ng•h/ml, which is estimated to provide
maximal inhibition of DDC, while lower carbidopa
concentrations could potentially compromise levodopa
bioavailability (31).

Frontiers in Neurology

Across these short-duration studies, there was no consistent
pattern of an increase in frequency (number of adverse
events), incidence (number of subjects with at least one
adverse event), or severity of adverse events (AEs) with
increasing infusion rates of ND0612. An overall summary
of AEs is given in Supplementary Table 2. All AEs assessed
as related to the study drug were mild or moderate in
severity, and none of them led to premature treatment
discontinuation. The most common AEs were infusion site
reactions and/or pain at the infusion site. There were no
clinically significant treatment-emergent changes in any clinical
laboratory parameters, vital signs, ECG parameters, or physical
examination findings.

Discussion
Subcutaneous infusion of levodopa may provide a welltolerated and convenient route of continuous levodopa delivery.
However, until the development of ND0612, the poor solubility
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gastrointestinal tract, the stable concentrations of levodopa
achieved support ND0612 as a potential parenteral formulation
for achieving clinically useful delivery of levodopa for
PD patients.
It is generally agreed that plasma levodopa concentration
need to be maintained above a certain threshold to achieve
sustained relief of PD symptoms. Several investigations have
estimated this threshold concentration to be about 1,000 ng/ml
(14, 33, 34). In this series of investigations, subcutaneous
infusion of “high” doses of ND0612 consistently remained above
this threshold and avoided the troughs below the concentrations
associated with OFF episodes. Even when lower dosing regimens
were trialed in Study 003, continuous SC administration of
ND0612 ameliorated both the troughs in levodopa plasma
concentrations and the variability in levodopa concentrations
(as reflected by the Fluctuation Index vs. placebo). The
Fluctuation Index is a measure of the magnitude of rise
and fall of levodopa plasma concentrations relative to the
average concentration; the lower the Fluctuation Index, the
more likely the Cmax is blunted relative to the trough, thereby
minimizing potential Cmax -related adverse effects [including
peak-effect dyskinesia (33)]. From these data, it is reasonable
to believe that treatment with NDO612 should also ameliorate
dyskinesia (since the Cmax is lower for ND0612 vs. oral
formulations). However, a limitation of current and ongoing
studies is that they focus on a population of patients primarily
suffering from OFF time. In Study 004, both the low and
high ND0612 regimens maintained near-constant, therapeutic
levodopa plasma concentrations.
Of particular note, the development plan considered that
the ideal dosing of carbidopa with levodopa has never been fully
established—even for oral formulations. Previous preclinical
studies have shown that when carbidopa is continuously
delivered subcutaneously, levodopa pharmacokinetics are
improved as compared to oral carbidopa administration (35).
In part, this may be because there is evidence for inconsistent
uptake of oral carbidopa from the gastrointestinal tract. This
inconsistency could add to the variability of oral levodopa effect
(36). In Study 005 (conducted in 20 healthy volunteers), the
concentration of SC infused carbidopa that achieved optimal
levodopa bioavailability was found to be 7.5 mg/ml when
co-administered with SC levodopa at 60 mg/ml. In other
studies, higher carbidopa concentrations did not increase
bioavailability of levodopa, though lower concentrations of
carbidopa when administered at the “low” infusion rates were
found to compromise the levodopa levels—probably due to
insufficient inhibition of the DDC enzyme. Thus, taken together,
the data generated in this series of investigations found that
a levodopa/carbidopa dose ratio of 1:8 would be the most
reasonable choice for proceeding with ND0612 in Phase III
clinical trials. The choice of the solubilized constituents in
ND0612 is now fixed as carbidopa 7.5 mg/ml together with
levodopa 60 mg/ml.

FIGURE 3

Levodopa plasma levels (logarithmic scale) in patients with PD
experiencing motor ﬂuctuations treated with (A) standard of
care (SoC) levodopa (N = 30) (B) SoC levodopa plus ND0612
infusion (N = 19)* (C) SoC levodopa plus placebo infusion (N =
11)*. *Standard of care levodopa plus ND0612 (60/14 mg/ml) or
placebo infused at a rate of 0.08 ml/h over 8 h and 0.24 ml/h
over 16 h.

of levodopa precluded this approach. The series of studies
described above formed the basis for the final formulation of
ND0612 which is now in Phase III of its clinical development.
Taken together, the results demonstrate that subcutaneous
levodopa infusion achieves stable and sustained plasma
concentrations of levodopa as well as dose-proportionality with
plasma concentrations increasing with increased infusion rates.
Resulting from consistent administration and bypassing the
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FIGURE 4

Mean plasma levodopa levels following continuous SC administration of ND0612 over 8 h with varying rates and carbidopa concentrations.

The studies presented here also explored augmenting the
SC administration of ND0612 with oral levodopa/carbidopa,
administered either alone or in combination with the COMT
inhibitor entacapone. The supplemental use of these oral drugs
produced expected effects on plasma levodopa concentrations
and suggested ways that ND0612 could be used in future clinical
applications. These results indicate that oral levodopa/carbidopa
(with or without a COMT inhibitor) might be a way to lessen
the quantity of drug that would otherwise need to be delivered
subcutaneously to achieve therapeutic concentrations of
carbidopa and levodopa. This ability to predictably complement
continuous SC levodopa/carbidopa infusion with oral drugs
is likely to provide patients with the flexibility in dosing to
optimize their pharmacotherapy (and without the need to rely
on full-replacement SC levodopa/carbidopa monotherapy in
order to obtain the pharmacokinetic benefits of continuous
SC levodopa/carbidopa therapy). The ongoing BouNDless
study (NCT04006210) starts with a “conversion period” in
which each patient’s ND0612 treatment is optimized with
supplemental oral levodopa/carbidopa as necessary. Changes to
other antiparkinsonian medications are not permitted during
all periods of the study.

Frontiers in Neurology

We have described a series of early development
pharmacokinetic studies, which served as a “learning
curve” for understanding the peripheral pharmacokinetics
of subcutaneously delivered levodopa/carbidopa. At each stage
of the program, lessons were learned that impacted subsequent
planning and choice of study designs. As such, the studies
share the usual early development limitations of being relatively
small in size and duration. A population pharmacokinetic
model, including data from these studies and additional clinical
trials with pharmacokinetic data analyses, is in development.
Participants in these studies were predominantly White
Caucasians. A pharmacokinetic study in Japanese subjects has
already been initiated. Most of the studies tested abdominal
infusion placement, whereas in real-world applications, patients
will require rotation of sites due to the development of transient
infusion site reactions and some will use infusion sites on other
areas of the body with significant SC tissue. Recent results from
a study comparing the results of abdominal ND0612 infusion
with sites in the lower back and thighs confirm bioequivalence
from infusion at different sites (35) and peer reviewed data will
be published separately. While all the studies included safety
observations, the studies were too short to be of relevance and
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FIGURE 5

Mean plasma levodopa concentrations following continuous SC administration of ND0612 (high dose) with varying carbidopa concentrations.

of clinical pharmacokinetic investigations have demonstrated
that ND0612, administered continuously with a levodopa
concentration of 60 mg/ml together with carbidopa 7.5
mg/ml, and complemented with oral levodopa/carbidopa, is
suitable for administration for up to 24 h in patients with
PD. This formulation has been shown to be generally safe
and well-tolerated in an open-label, 12-month study of over
200 patients with PD (37) and we await the results of the
ongoing Phase III study which will establish whether the
favorable pharmacokinetic profile of ND0612 translates into
clinical efficacy.

the 1-year ND0612 safety data recently reported by Poewe et al.
(37) are much more informative. We note that the low dosing
regimens in the very earliest clinical development studies were
originally investigated to understand the feasibility of small
“patch pumps” in a less severe patient population. Ultimately, it
was decided to prioritize the development of the “high” dosing
regimen (up to 720/90 mg/day) infused over 16 and/or 24 h
because of the significant unmet needs of patients with poorly
controlled motor fluctuations. Therefore, this is the chosen
treatment regimen under investigation in ongoing clinical
trials (37, 38). While it could be argued that a key limitation
of the development program is the lack of information on the
pharmacokinetics of ND0612 monotherapy in patients with
PD, it is pertinent to note that ND0612 is not being developed
as a “complete” dopamine replacement therapy because
patients with motor fluctuations typically require relatively
high levodopa doses which would be impractical to deliver
as a subcutaneous infusion therapy due to skin tolerability.
Rather, ND0612 is intended as the next evolution in levodopa
delivery for patients with Parkinson’s disease. Future studies
may continue the development of lower dose ND0612 regimens
for patients who require less levodopa, potentially, with small
patch-pump style devices.
In summary, ND0612 is under development as a minimally
invasive drug-device combination to provide continuous
subcutaneous delivery of levodopa/carbidopa for patients with
PD experiencing motor fluctuations. Taken together, this series

Frontiers in Neurology
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